MBX Biosciences Inc. (NASDAQ:MBX) is one of the stocks that will double in 2026. On December 4, Goldman Sachs initiated coverage of MBX Biosciences with a Sell rating and $18 price target. The key ...
$240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, ...
CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...
Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no ...
Fintel reports that on July 16, 2025, Oppenheimer initiated coverage of MBX Biosciences (NasdaqGS:MBX) with a Outperform recommendation. Analyst Price Forecast Suggests 207.65% Upside As of June 20, ...
It’s an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics all going public with fine-tuned offerings. Of today’s three Nasdaq debuts, Bicara is set to make the ...
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 ...
Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 2025 MBX 4291 Phase 1 trial initiation in obesity anticipated in Q3 2025 $224.9 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results